June 25, 2021. The Court in the Insulet securities matter (District Court of Massachusetts) approved a class action settlement in the amount of $19.5 million. Plaintiffs alleged that the company misled investors about the success of its new insulin infusion system, the system’s patient adoption and growth rates, and associated financial projections. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided an expert report on market efficiency and consulted on the computation of damages.


Read more on this case at Stanford Securities Class Action Clearinghouse.